Literature DB >> 7853525

Human immunodeficiency virus type 1 Nef protein inhibits activation pathways in peripheral blood mononuclear cells and T-cell lines.

A Greenway1, A Azad, D McPhee.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) Nef protein causes the loss of cell surface CD4 and interleukin-2 (IL-2) receptor (Tac) from peripheral blood mononuclear cells (PBMC) and CD4+ T-cell lines. As both CD4 and the IL-2 receptor play crucial roles in antigen-driven helper T-cell signalling and T-cell proliferation, respectively, the role of Nef in the viral life cycle may be to perturb signalling pathways emanating from these receptors. However, the intracellular targets for Nef that result in receptor down-regulation are unknown. Using a recombinant glutathione S-transferase-full-length 27 kDa Nef (Nef27) fusion protein, produced in Escherichia coli by translation from the first start codon of HIV-1 nef clone pNL4-3, as an affinity reagent to probe cytoplasmic extracts of MT-2 cells and PBMC, we have shown interaction with at least seven host cell protein species ranging from 24 to 75 kDa. Immunoblotting identified four of these proteins as p56lck, CD4, p53, and p44mapk/erk1, all of which are intimately involved in intracellular signalling. To assess the relevance of these interactions and further define the biochemical activity of Nef in signal transduction pathways, highly purified Nef27 protein was introduced directly into PBMC by electroporation. Nef27-treated PBMC showed reduced proliferative responsiveness to exogenous recombinant IL-2. Normally, stimulation of T-cells by IL-2 or phorbol 12-myristate 13-acetate provokes both augmentation of p56lck activity and corresponding posttranslational modification of p56lck. These changes were also inhibited by treatment of PBMC with Nef, suggesting that Nef interferes with activation of p56lck and as a consequence of signalling via the IL-2 receptor. Further evidence for Nef interfering with cell proliferation was the decreased production of the proto-oncogene c-myb, which is required for cell cycle progression, in Nef-treated MT-2 cells. In contrast to the binding characteristics and biological effects of Nef27, the alternate 25-kDa isoform of Nef (Nef25) produced by translation from the second start codon of HIV nef pNL4-3 (57 nucleotide residues downstream) was shown to interact with only three cellular proteins of approximately 26, 28, and 56 kDa from PBMC and MT-2 cells, one of which was identified as p56lck. Also, proliferation and posttranslational modification of p56lck in response to IL-2 stimulation were not profoundly affected by treatment of PBMC with Nef25 compared with Nef27.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7853525      PMCID: PMC188795     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  Expression of the CD4 gene requires a Myb transcription factor.

Authors:  G Siu; A L Wurster; J S Lipsick; S M Hedrick
Journal:  Mol Cell Biol       Date:  1992-04       Impact factor: 4.272

2.  Biochemical and biological comparison of HIV-1 NEF and ras gene products.

Authors:  A R Nebreda; T Bryan; F Segade; P Wingfield; S Venkatesan; E Santos
Journal:  Virology       Date:  1991-07       Impact factor: 3.616

Review 3.  Regulation of human immunodeficiency virus replication.

Authors:  B R Cullen
Journal:  Annu Rev Microbiol       Date:  1991       Impact factor: 15.500

Review 4.  Expression and interactions of the Src family of tyrosine protein kinases in T lymphocytes.

Authors:  J B Bolen; P A Thompson; E Eiseman; I D Horak
Journal:  Adv Cancer Res       Date:  1991       Impact factor: 6.242

5.  p53-mediated cell death: relationship to cell cycle control.

Authors:  E Yonish-Rouach; D Grunwald; S Wilder; A Kimchi; E May; J J Lawrence; P May; M Oren
Journal:  Mol Cell Biol       Date:  1993-03       Impact factor: 4.272

6.  Human immunodeficiency virus type 1 Nef protein inhibits NF-kappa B induction in human T cells.

Authors:  T M Niederman; J V Garcia; W R Hastings; S Luria; L Ratner
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

7.  The negative effect of human immunodeficiency virus type 1 Nef on cell surface CD4 expression is not species specific and requires the cytoplasmic domain of CD4.

Authors:  J V Garcia; J Alfano; A D Miller
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

8.  The HIV-1 nef protein does not have guanine nucleotide binding, GTPase, or autophosphorylating activities.

Authors:  J M Backer; C E Mendola; J L Fairhurst; I Kovesdi
Journal:  AIDS Res Hum Retroviruses       Date:  1991-12       Impact factor: 2.205

9.  Altered T cell activation and development in transgenic mice expressing the HIV-1 nef gene.

Authors:  J Skowronski; D Parks; R Mariani
Journal:  EMBO J       Date:  1993-02       Impact factor: 11.598

10.  Association of p56lck with IL-2 receptor beta chain is critical for the IL-2-induced activation of p56lck.

Authors:  Y Minami; T Kono; K Yamada; N Kobayashi; A Kawahara; R M Perlmutter; T Taniguchi
Journal:  EMBO J       Date:  1993-02       Impact factor: 11.598

View more
  36 in total

1.  Mutation of a conserved residue (D123) required for oligomerization of human immunodeficiency virus type 1 Nef protein abolishes interaction with human thioesterase and results in impairment of Nef biological functions.

Authors:  L X Liu; N Heveker; O T Fackler; S Arold; S Le Gall; K Janvier; B M Peterlin; C Dumas; O Schwartz; S Benichou; R Benarous
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

Review 2.  A portrait of the Bcl-2 protein family: life, death, and the whole picture.

Authors:  M Pellegrini; A Strasser
Journal:  J Clin Immunol       Date:  1999-11       Impact factor: 8.317

3.  The Nef protein of HIV-1 associates with rafts and primes T cells for activation.

Authors:  J K Wang; E Kiyokawa; E Verdin; D Trono
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

4.  Direct binding of human immunodeficiency virus type 1 Nef to the major histocompatibility complex class I (MHC-I) cytoplasmic tail disrupts MHC-I trafficking.

Authors:  Maya Williams; Jeremiah F Roeth; Matthew R Kasper; Rebekah I Fleis; Chris G Przybycin; Kathleen L Collins
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

5.  A role for natural simian immunodeficiency virus and human immunodeficiency virus type 1 nef alleles in lymphocyte activation.

Authors:  L Alexander; Z Du; M Rosenzweig; J U Jung; R C Desrosiers
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 6.  HIV-1 Nef control of cell signalling molecules: multiple strategies to promote virus replication.

Authors:  Alison L Greenway; Gavan Holloway; Dale A McPhee; Phoebe Ellis; Alyssa Cornall; Michael Lidman
Journal:  J Biosci       Date:  2003-04       Impact factor: 1.826

7.  Mutational analysis of human immunodeficiency virus type 1 (HIV-1) accessory genes: requirement of a site in the nef gene for HIV-1 replication in activated CD4+ T cells in vitro and in vivo.

Authors:  Y Kawano; Y Tanaka; N Misawa; R Tanaka; J I Kira; T Kimura; M Fukushi; K Sano; T Goto; M Nakai; T Kobayashi; N Yamamoto; Y Koyanagi
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

8.  Mechanism of Nef-induced CD4 endocytosis: Nef connects CD4 with the mu chain of adaptor complexes.

Authors:  V Piguet; Y L Chen; A Mangasarian; M Foti; J L Carpentier; D Trono
Journal:  EMBO J       Date:  1998-05-01       Impact factor: 11.598

9.  Functional characterization of human immunodeficiency virus type 1 nef genes in patients with divergent rates of disease progression.

Authors:  N L Michael; G Chang; L A d'Arcy; C J Tseng; D L Birx; H W Sheppard
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

10.  Nef-induced CD4 and major histocompatibility complex class I (MHC-I) down-regulation are governed by distinct determinants: N-terminal alpha helix and proline repeat of Nef selectively regulate MHC-I trafficking.

Authors:  A Mangasarian; V Piguet; J K Wang; Y L Chen; D Trono
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.